Skip to main content
. 2024 Dec 18;15(12):913. doi: 10.1038/s41419-024-07297-y

Fig. 5. In vitro experiments to validate the effect of exosomal miR-320d on vascular endothelial angiogenic capacity and on the JAK2/STAT3 pathway.

Fig. 5

A Analysis of GSE dataset revealing high expression of miR-320d in patients with lymphovascular invasion. B Correlation analysis of miR-320d expression with scores of angiogenic capacity. C qPCR assay showing the effect of miR-320d mimics /inhibitor-Exos on VEGFA expression in vascular endothelial cells. D, E Impact of miR-320d mimics /inhibitor-Exos on the angiogenic capacity of vascular endothelial cells. F Effect of miR-320d mimics/inhibitor-Exos on JAK2/STAT3/VEGFA expression in HUVEC. G Role of serum exosomal miR-320d in predicting the efficacy of bevacizumab chemotherapy in CRC non-responder n = 23; Responder n = 14. (Two-tailed unpaired t-test or Mann–Whitney test *P < 0.05, **P < 0.01, ***P < 0.001).